Indication
Real-world Outcome
1 clinical trial
5 products
Clinical trial
The Most Appropriate Prescription of the First-line, the Second-line, and the Third Treatment for H. Pylori Eradication Among Patients Who Are Comorbid Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, or Chronic Kidney DiseaseStatus: , Estimated PCD: 2023-12-31
Product
The sequential therapyProduct
The triple therapyProduct
The Hybrid TherapyProduct
The concomitant therapy